In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Semler Scientific (SMLR – Research Report), with a price target of $65.00. The company’s shares closed yesterday at $28.15.
According to TipRanks, O’Neil is an analyst with an average return of -1.1% and a 42.92% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, ModivCare, and Augmedix.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Semler Scientific with a $65.00 average price target.
The company has a one-year high of $53.38 and a one-year low of $22.82. Currently, Semler Scientific has an average volume of 78.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Semler Scientific (SMLR) Company Description:
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in San Jose, CA.
Read More on SMLR:
